Nanomedicines in the treatment of methicillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a formidable global health threat by evading conventional antibiotics and constraining therapeutic options. This review examines the clinical impasse and maps a rapidly expanding nanotechnological arsenal poised to overcome it. First, we delineate the molecular and pharmacological limitations of β-lactams, glycopeptides, and next-line agents, emphasizing the urgent need for orthogonal strategies. Central to this review are five converging nanodesign paradigms. Inorganic and metallic nanoconstructs, such as silver and gold colloids, magnetically responsive iron oxides, and near-infrared photothermal systems, exploit elemental properties to disrupt biofilms, catalyze reactive oxygen species, and induce localized hyperthermia. Mesoporous silica and graphene oxide-based platforms offer programmable porosity and surface tunability, allowing enzyme functionalization to degrade extracellular matrices and re-sensitize persister cells. Biomimetic and stimuli-responsive nanoparticles enhance targeting by cloaking in cellular membranes or releasing payloads in acidic, enzyme-rich MRSA environments. Hybrid constructs integrate antibiotics, photothermal triggers, or CRISPR-based gene editors to achieve synergistic effects while mitigating resistance evolution. Recognizing delivery bottlenecks, we highlight depot-forming hydrogels and thermoresponsive injectables that solidify in situ, maintaining high local drug concentrations within abscesses or infected bone. The review concludes by addressing translational challenges, including scalable synthesis, immunotoxicity, AI-guided formulation design, and regulatory alignment. Collectively, these advances signify a paradigm shift from empirical pharmacology to precision-engineered therapeutics, redefining MRSA as a tractable target amenable to multi-pronged clinical intervention.